NEWAMSTERDAM PHARMA COMPANY N.V.

Analyst Reco. NewAmsterdam Pharma Company N.V. Nasdaq

Equities

NAMS

NL00150012L7

Market Closed - Nasdaq Other stock markets 21:00:00 26/06/2024 BST			5-day change	1st Jan Change
19.75 ^USD	+0.41%		+15.43%	+76.81%

06-11	NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	MT
06-10	Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Starts NewAmsterdam Pharma With Buy Rating	05-15	MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target	03-14	MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk	02-29	MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target	01-18	MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target	30/10/23	MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating	03/04/23	MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target	06/01/23	MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target	20/12/22	MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target	20/12/22	MT
William Blair Starts NewAmsterdam Pharma at Outperform	19/12/22	MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target	19/12/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer